fda compounding semaglutide warning letters news Sends 30 To Continue Clampdown on Compounded GLP-1s Navigating Compounded Semaglutide: What Health

No peptide can guarantee the prevention of loose skin, especially with very large weight losses or in patients with reduced skin elasticity due to age, genetics, or sun damage

If independent testing is important to your study, arrange analysis through a qualified facility and review the lot-specific documentation policy before purchase

Long-Term Safety Data Still Limited The longest published Retatrutide data extends to 68 weeks from the TRIUMPH-4 trial

Some patients transition to maintenance doses rather than stopping entirely

Circulating plasma GLP-1 levels rise from approximately 510 pmol/L in the fasted state to 1550 pmol/L in the postprandial state, with peak levels depending on meal composition, caloric density, and rate of gastric emptying

The cardiovascular safety of semaglutide has been studied extensively, most notably in the SUSTAIN-6 trial (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes)